Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04975997
Trial Phases:	Phase III	Protocol IDs:	CC-220-MM-002 (primary) NCI-2021-08518 2020-000431-49 U1111-1260-2872
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Celgene
NCI Full Details:	http://clinicaltrials.gov/show/NCT04975997

Summary

Objectives

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study
comparing the efficacy and safety of iberdomide in combination with dexamethasone and
daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in
participants with relapsed or refractory multiple myeloma (RRMM). Approximately 200
patients randomized in stage 1 to one of three iberdomide dose levels of 1, 1.3, or 1.6
mg in combination with daratumumab and dexamethasone (Treatment Arms A1, A2, or A3), or
to the DVd comparator arm (Treatment Arm B).

In Stage 2 of the study, approximately 664 additional subjects will be randomized 1:1
between 2 treatment arms:

- Approximately 332 subjects will be randomized to receive Treatment Arm A (IberDd)

- Approximately 332 subjects will be randomized to receive Treatment Arm B (DVd)

Participants in both treatment arms will continue to receive treatment until confirmed
progressive disease (PD), unacceptable toxicity or withdrawal of consent. To ensure
accuracy and completeness of the primary endpoint assessment of progression-free survival
(PFS), participants who permanently discontinue study treatment for any reason, other
than confirmed PD or withdrawal of consent, will continue to be followed for disease
assessment.

The study will be conducted in compliance with International Council for Harmonisation
(ICH) and Good Clinical Practices (GCPs).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.